Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review
Authors:
- 1 July 2019
- journal article
- review article
- Published by Medknow in Singapore Medical Journal
- Vol. 60 (7) , 364-378
Abstract
Osteoporosis is the main cause of fractures among women after menopause. This study aimed to evaluate the efficacy and safety of denosumab compared to bisphosphonates in treating postmenopausal osteoporosis. Databases including PubMed and the Cochrane Central Register of Controlled Trials were systematically searched for randomised controlled trials (RCTs) that directly compared denosumab and bisphosphonates. RCTs that studied both denosumab and bisphosphonates in postmenopausal women with osteoporosis and had a Jadad score ≥ 3 were included. Nine studies were eligible for inclusion. They were further categorised into six cohort groups. All studies had denosumab with oral bisphosphonates as the active comparator. Four out of six cohort studies showed significant improvements in bone strength (p < 0.001) at the distal radius, tibia, total hip, femoral neck, lumbar spine and trochanter at 12 months for patients on denosumab compared to the bisphosphonate group. Serum C-telopeptide of cross-linked collagen, a bone turnover marker, was consistently lower in the denosumab group in all studies. There were no significant differences in hypocalcaemia, atypical fractures, fragility fractures, osteonecrosis of the jaw, all infections (including fever or influenza-like symptoms), gastrointestinal side effects or dermatological conditions in all studies, except for one that did not document side effects. Denosumab can be used both as a first-line agent and an alternative to bisphosphonate in the treatment of postmenopausal osteoporosis. There is currently insufficient data to show that denosumab is not inferior to bisphosphonates in fracture prevention.Keywords
This publication has 29 references indexed in Scilit:
- Cortical Hand Bone Porosity and Its Association with Distal Radius Fracture in Middle Aged and Elderly WomenPLOS ONE, 2013
- Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysisInternational Journal Of Clinical Practice, 2012
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapyJournal of Bone and Mineral Research, 2010
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 TrialJournal of Bone and Mineral Research, 2009
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMDJournal of Bone and Mineral Research, 2007
- Intervention thresholds for osteoporosis in the UKBone, 2005
- Osteoclast differentiation and activationNature, 2003
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998